p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming

p62/Sqstm1 is a multifunctional protein involved in cell survival, growth and death, that is degraded by autophagy. Amplification of the p62/Sqstm1 gene, and aberrant accumulation and phosphorylation of p62/Sqstm1, have been implicated in tumour development. Herein, we reveal the molecular mechanism...

Full description

Saved in:
Bibliographic Details
Published inNature communications Vol. 7; no. 1; pp. 12030 - 16
Main Authors Saito, Tetsuya, Ichimura, Yoshinobu, Taguchi, Keiko, Suzuki, Takafumi, Mizushima, Tsunehiro, Takagi, Kenji, Hirose, Yuki, Nagahashi, Masayuki, Iso, Tetsuro, Fukutomi, Toshiaki, Ohishi, Maki, Endo, Keiko, Uemura, Takefumi, Nishito, Yasumasa, Okuda, Shujiro, Obata, Miki, Kouno, Tsuguka, Imamura, Riyo, Tada, Yukio, Obata, Rika, Yasuda, Daisuke, Takahashi, Kyoko, Fujimura, Tsutomu, Pi, Jingbo, Lee, Myung-Shik, Ueno, Takashi, Ohe, Tomoyuki, Mashino, Tadahiko, Wakai, Toshifumi, Kojima, Hirotatsu, Okabe, Takayoshi, Nagano, Tetsuo, Motohashi, Hozumi, Waguri, Satoshi, Soga, Tomoyoshi, Yamamoto, Masayuki, Tanaka, Keiji, Komatsu, Masaaki
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 27.06.2016
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:p62/Sqstm1 is a multifunctional protein involved in cell survival, growth and death, that is degraded by autophagy. Amplification of the p62/Sqstm1 gene, and aberrant accumulation and phosphorylation of p62/Sqstm1, have been implicated in tumour development. Herein, we reveal the molecular mechanism of p62/Sqstm1-dependent malignant progression, and suggest that molecular targeting of p62/Sqstm1 represents a potential chemotherapeutic approach against hepatocellular carcinoma (HCC). Phosphorylation of p62/Sqstm1 at Ser349 directs glucose to the glucuronate pathway, and glutamine towards glutathione synthesis through activation of the transcription factor Nrf2. These changes provide HCC cells with tolerance to anti-cancer drugs and proliferation potency. Phosphorylated p62/Sqstm1 accumulates in tumour regions positive for hepatitis C virus (HCV). An inhibitor of phosphorylated p62-dependent Nrf2 activation suppresses the proliferation and anticancer agent tolerance of HCC. Our data indicate that this Nrf2 inhibitor could be used to make cancer cells less resistant to anticancer drugs, especially in HCV-positive HCC patients. Dysregulation of p62 has been implicated in tumorigenesis. Here, the authors show that p62 promotes hepatocellular carcinoma by reprogramming glucose and glutamine metabolism through Nrf2 and present a novel compound that can inhibit p62 action thus sensitizing cancer cells to chemotherapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2041-1723
2041-1723
DOI:10.1038/ncomms12030